If you are looking to invest in companies that aim to provide disruptive technology to the healthcare sector, there can be plenty of intriguing options. While some of those may lack a solid foundation to build a high-quality business on, 10x Genomics (NASDAQ: TXG) and DermTech (NASDAQ: DMTK) don't suffer from that issue, and each is well worth your consideration.
Both have immense potential, but which stock is a better buy today? Two Motley Fool contributors battle it out to answer this question.
Image Source: Getty Images.
For further details see:
Better Buy: 10x Genomics vs. DermTech